News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NHWA Pharma Gains China Fast-Track For Epilepsy Drug


6/30/2014 11:56:00 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Jiangsu NHWA Pharma announced that DP-VPA, its in-licensed epilepsy treatment, was granted Fast Track designation by the CFDA. DP-VPA combines a well-known generic drug for epilepsy, valproic acid (VPA), with a lipid coating to minimize side effects. In 2011, NHWA acquired exclusive China rights (including Hong Kong and Macau) to DP-VPA from D-Pharm, an Israeli biopharma.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
 
 
Epilepsy

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES